ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT
For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozol...
Saved in:
| Main Authors: | J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, A. Makris, J.W.R. Nortier, K. Possinger, L.-E. Rutqvist |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-09-01
|
| Series: | Опухоли женской репродуктивной системы |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin-like growth factor-binding protein-3 is induced by tamoxifen and fulvestrant and modulates fulvestrant response in breast cancer cells
by: Keenan L. Flynn, et al.
Published: (2024-11-01) -
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
by: Jiayu Wang, et al.
Published: (2025-04-01) -
Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer
by: Karam Aboud, et al.
Published: (2025-07-01) -
Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
by: Binghe Xu, et al.
Published: (2025-01-01) -
Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant
by: Scott Thomas, et al.
Published: (2025-01-01)